30 / 64
Primera línea: cerrado para reclutamiento
IMmotion151
PD-L1 + VEGF inhibition
Atezolizumab; n=70
Phase III
Sunitinib
Atezolizumab +
b i
b
50 mg/day 4/2
R
n=830
evac zuma
1200 mg IV +
15 mg/kg IV every 3 weeks
Co-Primary endpoint: PFS, OS
https://clinicaltrials.gov/ct2/show/NCT02420821; McDermott DF, et al. J Clin Oncol 2016; Wallin JJ, et al. Nat Commun 2016